Paroxysmal AF
17
6
10
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.4% vs benchmark
6%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (17)
FARAPULSE™ Pulsed Field Ablation System
Feasibility Study of the FARAFLEX Mapping and PFA System
Durability of Pulmonary Vein Isolation Using a Variable-Loop Biphasic Pulsed Field Ablation Catheter in Patients With Paroxysmal Atrial Fibrillation
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
PulseMagic™ TrueForce™ PAF NMPA Study
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
3-Dimensional Mapping System: The PULSTAR II Study
The Effect of Pulse Field Ablation of Atrial Fibrillation Involving Posterior Wall Ablation on Atrial Mechancis Assessed by Cardiac Magnetic Resonance Imaging
Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration
SVC-isolation in Redo-AF Ablation With Isolated PV
Evaluation of the Impact of Pulsed Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation
AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man
CARTO® 3 System and Real Time Intracardiac Ultrasound